Fever with Severe Joint Pains - Clinical Approach

Differential Diagnosis

1. Septic (Infectious) Arthritis

• Classically subacute monoarticular joint pain with low-grade fever; fever > 39°C is rare
• Knee is the most commonly affected joint; polyarticular in < 15%
• Most common organism: Staphylococcus aureus, followed by streptococcal species
• Risk factors: recent joint surgery (LR+ 6.9), prosthetic joint + skin infection, IV drug use
• Over 40% of confirmed cases are afebrile - so absence of fever does not rule it out
• Key point: a single acutely inflamed joint should be presumed infected until proved otherwise
• Symptom to Diagnosis, 4th Ed.

2. Disseminated Gonococcal Infection (DGI)

• Classic presentation: young sexually active woman, fever + severe pain in wrists, hands, and knees with erythema over backs of hands; rash may be present
• Women are 3x more likely than men
• Symptom to Diagnosis, 4th Ed.

3. Rheumatic Fever (Acute)

• Follows streptococcal pharyngitis by 2-4 weeks
• Classic migratory polyarthritis - individual joints affected for < 1 week each; legs first
• Jones Criteria - major: carditis, polyarthritis, chorea, erythema marginatum, subcutaneous nodules
• In adults: prior strep infection often not documented; joint pain and stiffness are the dominant features
• Symptom to Diagnosis, 4th Ed.

4. Reactive Arthritis (Reiter's Syndrome)

• Asymmetric mono/oligoarthritis of lower extremities following enteric or urogenital infection
• High suspicion warranted in young patient with inflammatory, asymmetric oligoarthritis
• Most resolve within 1 year; NSAIDs for acute symptoms; treat underlying infection if culture-positive
• Symptom to Diagnosis, 4th Ed.

5. Chikungunya Fever (key in tropical regions)

• Transmitted by Aedes mosquito; endemic in Africa, India, Southeast Asia, Caribbean
• Abrupt onset of high fever + severe joint symptoms (in 40% of infected; approaches 100% in those with rash)
• Swelling and pain predominantly in small joints of hands and feet
• Joint symptoms may persist for weeks to months (~50% symptomatic at 6 months)
• Morbilliform rash appears by day 2 in >50%; lymphopenia, thrombocytopenia, elevated LFTs
• Diagnosis: virus-specific IgM; confirmation by IgG seroconversion; PCR in acute phase
• Andrews' Diseases of the Skin; Goldman-Cecil Medicine

6. Dengue Fever

• Also transmitted by Aedes, same endemic regions as chikungunya - can be difficult to distinguish
• Arthralgia/myalgia prominent ("breakbone fever")
• Neutropenia in 80% of dengue vs. only 10% of chikungunya - a useful differentiator
• Andrews' Diseases of the Skin

7. Crystal Arthropathies (Gout / Pseudogout)

• Can present with fever, acute joint pain, and elevated acute-phase reactants
• Gout: hyperuricemia, urate crystals; podagra (first MTP joint) is classic
• Pseudogout (CPPD): calcium pyrophosphate crystals; wrists, MCPs, shoulders - atypical joints for OA
• Septic arthritis can mimic pseudogout/gout - always consider joint aspiration
• Goldman-Cecil Medicine

8. Viral Arthritis (Other)

• Rubella / rubella vaccine: transient arthritis in up to 70% of adults after rubella infection
• Parvovirus B19: symmetric small joint arthritis, often with rash (fifth disease in children)
• Zika virus: similar to chikungunya - fever + arthralgia/arthritis; same geographic distribution
• Hepatitis B/C: prodromal arthritis before jaundice appears
• Harrison's Principles of Internal Medicine 22E; Goldman-Cecil Medicine

9. Adult-Onset Still's Disease (AOSD)

• Quotidian fever spike (high-spiking then normalizing), salmon-colored evanescent rash, arthritis, leukocytosis
• Diagnosis of exclusion

10. Lyme Disease (in endemic areas)

• Migratory arthritis, large joints (especially knee); tick exposure history
• Differential includes septic arthritis, gonococcal arthritis, rheumatic fever
• Rosen's Emergency Medicine

Diagnostic Workup

Key Clinical Clues

Treatment Overview

• Septic arthritis: IV antibiotics (empirically cover S. aureus) + joint drainage (serial aspiration or surgical); early treatment (within 5 days) = best prognosis
• Rheumatic fever: penicillin + NSAIDs for arthritis; carditis managed separately
• Reactive arthritis: NSAIDs; antibiotics if active infection confirmed
• Gout/Pseudogout: NSAIDs, colchicine, or joint injection with corticosteroids
• Chikungunya/Dengue: supportive; NSAIDs (avoid in dengue due to bleeding risk - use paracetamol)
• DGI: ceftriaxone

Clinical priority: In any patient with fever + a single acutely swollen joint, joint aspiration is mandatory to rule out septic arthritis before any treatment is started, as delay risks permanent joint destruction.

Chikungunya - Treatment

Key Principle: No Specific Antiviral

Acute Phase Treatment (First 7-10 Days)

Critical rule: In areas where dengue is co-endemic (which includes most of tropical Asia, Africa, and the Americas), avoid NSAIDs initially until dengue is ruled out. If dengue is present, NSAIDs can precipitate hemorrhagic complications. Use paracetamol only until dengue is excluded.

Subacute / Chronic Phase (Persistent Joint Symptoms > 10 Days)

Severe / Complicated Disease

• Neonates with perinatal exposure
• Adults > 65 years
• Patients with hypertension, diabetes, cardiovascular, or kidney disease

Prevention and Vector Control

• Insect repellent (DEET, picaridin)
• Long-sleeved clothing
• Screened/air-conditioned rooms
• Limit outdoor activity during peak Aedes mosquito feeding times (daytime)
• Febrile patients should be protected from mosquito bites to prevent further spread

Diagnosis Reminder

• Red Book 2021, Report of the Committee on Infectious Diseases, p. 451
• Andrews' Diseases of the Skin, Clinical Dermatology

Latest WHO & CDC Guidelines for Chikungunya (2025-2026)

WHO - New 2025 Guidelines

• WHO Chikungunya Outbreak Toolbox
• Policy Considerations for Strengthening Preparedness and Response to Arbovirus Epidemics and Pandemics (16 July 2025)
• WHO Rapid Risk Assessment: Chikungunya Virus, Global (December 2025)

• Strengthen integrated surveillance (epidemiological, clinical, laboratory, entomological)
• RT-PCR in first week; IgM serology after day 5-7
• Supportive clinical management (see below)
• Vector control: larval source reduction, household spraying, fogging
• Community engagement and early care-seeking campaigns

CDC (Yellow Book 2025) - Treatment Guidelines

Treatment

No specific antiviral treatment exists, though several are under investigation.

Vaccine - Major 2025-2026 Update

IXCHIQ (Valneva) - WITHDRAWN / LICENSE SUSPENDED

• Was the first FDA-approved chikungunya vaccine (live-attenuated, November 2023)
• FDA suspended its license in August 2025 due to identification of serious adverse events in post-marketing surveillance
• Valneva withdrew the license application in January 2026
• IXCHIQ may still be available/used in some other countries

VIMKUNYA (Bavarian Nordic) - Currently Recommended in the US

• Virus-like particle (VLP) vaccine - not live-attenuated
• FDA-approved February 2025 for adults and adolescents aged ≥ 12 years
• Administered as a single 0.8 mL intramuscular dose
• Safer profile (not live) compared to IXCHIQ

ACIP 2025 Vaccine Recommendations

• Vaccine decision should be individualized based on: destination outbreak status, duration of travel, underlying medical conditions, traveler's preferences
• Travelers with underlying medical conditions, and women late in pregnancy (fetal risk) should consider avoiding travel to outbreak areas

PAHO/WHO Americas Alert (August 2025)

• Strengthen surveillance and diagnosis
• Ensure timely and appropriate case treatment
• Intensify vector prevention and control
• Prepare health care services for patient access to adequate care

Summary of Key 2025-2026 Changes